Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years
Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein, frequently overexpressed in hematological malignancies. Venetoclax was approved by the Food and Drug Administration for chronic lymph...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2025-07-01
|
| Col·lecció: | Therapeutic Advances in Hematology |
| Accés en línia: | https://doi.org/10.1177/20406207251343116 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|